TrialSignal
Clinical trial intelligence report
Evaluation of the Kinetics of mRNA Expression After Two Doses of GSK Biologicals' Candidate Tuberculosis (Tuberculosis) Vaccine GSK 692342 in Healthy Adults
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01669096
Status
COMPLETED
Phase
Phase 2
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
GSK's candidate tuberculosis vaccine, GSK 692342, aims to enhance immune response through mRNA expression profiling. Given the global burden of tuberculosis, particularly in developing regions, successful development could position GSK favorably in the vaccine market. The competitive landscape includes established vaccines like BCG and emerging candidates from other biopharma companies. Diligence should focus on regulatory pathways, potential partnerships for distribution, and the evolving landscape of tuberculosis treatment and prevention strategies.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01669096
Indication
Tuberculosis
Modality
protein therapy
Target
mRNA expression modulation related to tuberculosis immunity
Intervention
GSK Biologicals' investigational TB vaccine GSK 692342
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.